An interventional study of Transcranial pulsed electromagnetic fields (T-PEMF) and Sham (No Treatment) in PARKINSON DISEASE (Disorder), sponsored by University of Southern Denmark. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by University of Southern Denmark · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Parkinson Disease with a site in Denmark — 12 open to participants now, 18 under way, 1 of them phase 3. Parkinson Disease · Denmark.
Among the 50 studies in Parkinson Disease with a site in Denmark, this one is the 16th largest by planned enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2026, is one of 23 with no phase, reaches primary completion later than 12 of the 17 other live ones, and was the 45th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →12 of the 50 studies in Parkinson Disease with a site in Denmark are open now. Recruiting first, the newest first:
Danish Research Centre for Magnetic Resonance · Sites in Denmark
Ages 18+ · Healthy volunteers
Danish Research Centre for Magnetic Resonance · Sites in Denmark
Ages 18–80
Aarhus University Hospital · Sites in Denmark
Ages 50–80
Hoffmann-La Roche · Sites in Denmark, United States, Australia and 14 more countries
Ages 50–85
Annemette Lokkegaard · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 75 across the 33 interventional studies, 90 across the 17 observational. Of the 29 that completed or were terminated, 7 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 50 have an industry lead sponsor. The 10 most frequent:
University of Southern Denmark is the lead sponsor of 337 studies on the registry; 47 are open to participants now.
University of Southern Denmark has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
6 of the studies in Parkinson Disease with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06324422University of AarhusExercise as Treatment of Fatigue in Parkinson´s Disease | 2026-12-01 |
| NCT05981261University of AarhusExperimental Pain in Parkinsons | 2027-01-01 |
| NCT07465107Annemette LokkegaardMotor and Cognitive Exercise in Parkinson's Disease. | 2027-02-14 |
| NCT06570824Danish Research Centre for Magnetic ResonancerTMS as an Intervention for Levodopa-induced Dyskinesia | 2027-05-01 |
| NCT07397377Danish Research Centre for Magnetic ResonanceprTMS as an Intervention for Bradykinesia in Parkinson's Disease | 2027-05-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies in Parkinson Disease with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn to what extent daily stimulation of the brain with transcranial pulsed electromagnetic fields (T-PEMF) works to treat persons with Parkinson's Disease. The main questions it aims to answer are:
The neuro-mechanical outcomes are compared with the "natural" progression of the disease as well as with a healthy reference group. Furthermore, it will be examined whether 12 months of T-PEMF treatment alters the need for medication intake.
Participants in the intervention group will:
Intervention Groups
Inclusion Criteria:
Exclusion Criteria:
Control Group with Parkinson's Disease
Inclusion Criteria:
Exclusion Criteria:
Healthy Reference Group:
Inclusion Criteria:
-The patient must be able to understand, accept, and complete the planned procedures
Exclusion Criteria:
Persons with Parkinson's disease receiving 30 min daily active T-PEMF for 12 months. The first 6 months are blinded, the last 6 months are not.
Device: Transcranial pulsed electromagnetic fields (T-PEMF)
Persons with Parkinson's disease receiving 30 min daily sham T-PEMF for 6 months followed by 6 moths of 30 min daily active T-PEMF. The first 6 month is blinded, the last 6 months are not.
Device: Transcranial pulsed electromagnetic fields (T-PEMF) · Device: Sham (No Treatment)
Persons with Parkinson's disease receiving no experimental treatment. The group is used to monitor natural course of the disease.
Health age-matched persons assessed once to obtain age-matched normal intervals of performance.
30 min daily stimulation with transcranial pulsed electromagnetic fields (50 Hz)
30 min daily the participants are using/wearing the T-PEMF device but no stimulation occurs
Sit-to-stand
Completion time of 5 repetition sit-tot-stand test at maximal speed performed on force plate.
Time frame: From enrollment to end of intervention assessed at baseline, after 6 months and after 12 months.
Tremor intensity
Postural tremor intensity assessed by accelerometer
Time frame: From enrollment to end of intervention assessed at baseline, after 6 months and after 12 months.
Rate of force development
Isometric rate of force development assessed by handgrip and knee extension
Time frame: From enrollment to end of intervention assessed at baseline, after 6 months and after 12 months.
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
The MDS-UPDRS will be reported as total score (0-260, higher scores indicate greater disease severity) and motor score (part III, 0-132, higher scores indicate greater disease severity).
Time frame: From enrollment to end of intervention assessed at baseline, after 6 months and after 12 months.
Cerebrospinal fluid biomarkers
Concentration of growth factors, cytokines and cytoskeletal proteins with special emphasis on erythropoietin (EPO), vascular endothelial growth factor (VEGF), brain-derived neutrophic factor (BDNF), glia cell derived neutrophilic factor (GDNF), Glucagon Like Peptide 1 (GLP1), interleukins and neurofilament light chain (NfL).
Time frame: From enrollment to end of intervention assessed at baseline, after 6 months and after 12 months. Assessment in the intervention groups only.
EMG
Electromyographic recordings of forearm and thigh muscles during motor assessments (sit-to-stand, isometric contractions, postural tremor assessment, handwriting). Applied for explorative analyses, thus exact outcomes are not yet specified. However, agonist drive and co-contraction ratio may be assessed.
Time frame: From enrollment to end of intervention assessed at baseline, after 6 months and after 12 months.
Hand writing
Hand writing test performed with ink pen on paper on top of tablet (digitalizing handwriting). Performed as an explorative assessment.
Time frame: From enrollment to end of intervention assessed at baseline, after 6 months and after 12 months.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Jan 2028, 23 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 23 months is close to that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Southern Denmark →